HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF
The present invention provides a heterocyclic compound represented by General Formula (1): wherein R1 is a group R5-Z1-, etc., Z1 is a lower alkylene group, etc., and R5 is a group represented by General Formula; wherein R13 is a hydrogen atom, etc., m is an integer from 1 to 5; R2 is a hydrogen ato...
Saved in:
Main Authors | , , , , , , , , , , , , , , , , , , , |
---|---|
Format | Patent |
Language | English Spanish |
Published |
19.05.2010
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The present invention provides a heterocyclic compound represented by General Formula (1): wherein R1 is a group R5-Z1-, etc., Z1 is a lower alkylene group, etc., and R5 is a group represented by General Formula; wherein R13 is a hydrogen atom, etc., m is an integer from 1 to 5; R2 is a hydrogen atom: Y is CH or N: A1 is a heterocyclic ring selected from the group consisting of indolediyl groups, wherein the heterocyclic ring may have at least one substituent: T is a group -CO-, etc.: R3 is a hydrogen atom, etc.: R4 is a lower alkyl group optionally substituted by one or more hydroxy groups, etc.: R3 and R4, together with the nitrogen atom to which they bind, may bind to each other and form a 5- to 10-membered saturated heterocyclic ring, wherein the heterocyclic ring may have at least one substituent. The heterocyclic compound of the present invention has excellent effects of suppressing the production of collagen and/or treating tumors.
La presente invención provee un compuesto heterocíclico representado por la fórmula general (1): (ver fórmula (1)) en la cual R1 es un grupo R5-Z1-, etc., Z1 es un grupo alquileno inferior, etc., y R5 es un grupo representado por la fórmula general; (ver fórmula) en la cual R13 es un átomo de hidrógeno, etc., m es un número entero que varía entre 1 y 5; R2 es un átomo de hidrógeno: Y es CH o N: A1 es un anillo heterocíclico seleccionado del grupo que consiste en grupos indoldi-ilo, donde el anillo heterocíclico puede tener al menos un sustituyente: T es un grupo -CO-, etc.: R3 es un átomo de hidrógeno, etc.: R4 es un grupo alquilo inferior, opcionalmente sustituido por uno o más grupos hidroxi, etc.: R3 y R4, junto con el átomo de nitrógeno al cual se unen, pueden unirse entre sí y formar un anillo heterocíclico de 5 a 10 miembros, saturado, donde el anillo heterocíclico puede tener al menos un sustituyente; el compuesto heterocíclico de la presente invención tiene efectos excelentes para suprimir la producción de colágeno y/o tratar tumores. |
---|---|
AbstractList | The present invention provides a heterocyclic compound represented by General Formula (1): wherein R1 is a group R5-Z1-, etc., Z1 is a lower alkylene group, etc., and R5 is a group represented by General Formula; wherein R13 is a hydrogen atom, etc., m is an integer from 1 to 5; R2 is a hydrogen atom: Y is CH or N: A1 is a heterocyclic ring selected from the group consisting of indolediyl groups, wherein the heterocyclic ring may have at least one substituent: T is a group -CO-, etc.: R3 is a hydrogen atom, etc.: R4 is a lower alkyl group optionally substituted by one or more hydroxy groups, etc.: R3 and R4, together with the nitrogen atom to which they bind, may bind to each other and form a 5- to 10-membered saturated heterocyclic ring, wherein the heterocyclic ring may have at least one substituent. The heterocyclic compound of the present invention has excellent effects of suppressing the production of collagen and/or treating tumors.
La presente invención provee un compuesto heterocíclico representado por la fórmula general (1): (ver fórmula (1)) en la cual R1 es un grupo R5-Z1-, etc., Z1 es un grupo alquileno inferior, etc., y R5 es un grupo representado por la fórmula general; (ver fórmula) en la cual R13 es un átomo de hidrógeno, etc., m es un número entero que varía entre 1 y 5; R2 es un átomo de hidrógeno: Y es CH o N: A1 es un anillo heterocíclico seleccionado del grupo que consiste en grupos indoldi-ilo, donde el anillo heterocíclico puede tener al menos un sustituyente: T es un grupo -CO-, etc.: R3 es un átomo de hidrógeno, etc.: R4 es un grupo alquilo inferior, opcionalmente sustituido por uno o más grupos hidroxi, etc.: R3 y R4, junto con el átomo de nitrógeno al cual se unen, pueden unirse entre sí y formar un anillo heterocíclico de 5 a 10 miembros, saturado, donde el anillo heterocíclico puede tener al menos un sustituyente; el compuesto heterocíclico de la presente invención tiene efectos excelentes para suprimir la producción de colágeno y/o tratar tumores. |
Author | NAKAGAWA, TAKASHI TABUSA, FUJIO MIYAJIMA, KEISUKE OHI, NAOTO KOJIMA, YUTAKA YOSHIDA, KENJI IIDA, MASATOSHI HARADA, YASUO SEKIGUCHI, KAZUO FUJITA, SHIGEKAZU TAKASU, HIDEKI KODAMA, TAKESHI MOTOYAMA, MASAAKI KAN, KEIZO MATSUYAMA, HIRONORI SAKAMOTO, MAKOTO YASUMURA, KOICHI HASHIMOTO, NORIKAZU SUMIDA, TAKUMI FUKUSHIMA, TAE |
Author_xml | – fullname: HASHIMOTO, NORIKAZU – fullname: TABUSA, FUJIO – fullname: KOJIMA, YUTAKA – fullname: TAKASU, HIDEKI – fullname: KAN, KEIZO – fullname: OHI, NAOTO – fullname: NAKAGAWA, TAKASHI – fullname: MIYAJIMA, KEISUKE – fullname: YASUMURA, KOICHI – fullname: YOSHIDA, KENJI – fullname: FUJITA, SHIGEKAZU – fullname: SEKIGUCHI, KAZUO – fullname: IIDA, MASATOSHI – fullname: MOTOYAMA, MASAAKI – fullname: HARADA, YASUO – fullname: KODAMA, TAKESHI – fullname: MATSUYAMA, HIRONORI – fullname: FUKUSHIMA, TAE – fullname: SUMIDA, TAKUMI – fullname: SAKAMOTO, MAKOTO |
BookMark | eNrjYmDJy89L5WSw8XANcQ3yd4509vF0VnD29w3wD_VzUXAE4gAPxyBfR2fX0BBPZ0cfiFywZ4inv59CiIdrkKu_Gw8Da1piTnEqL5TmZlBycw1x9tBNLciPTy0uSExOzUstifeNMDIwNDAwMLGwNHY0JkoRAI0WLBs |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | COMPUESTO HETEROCICLICO Y COMPOSICION FARMACEUTICA DEL MISMO. |
ExternalDocumentID | MX2010004893A |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_MX2010004893A3 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 14:55:38 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English Spanish |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_MX2010004893A3 |
Notes | Application Number: MX20100004893 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20100519&DB=EPODOC&CC=MX&NR=2010004893A |
ParticipantIDs | epo_espacenet_MX2010004893A |
PublicationCentury | 2000 |
PublicationDate | 20100519 |
PublicationDateYYYYMMDD | 2010-05-19 |
PublicationDate_xml | – month: 05 year: 2010 text: 20100519 day: 19 |
PublicationDecade | 2010 |
PublicationYear | 2010 |
RelatedCompanies | OTSUKA PHARMACEUTICAL CO., LTD |
RelatedCompanies_xml | – name: OTSUKA PHARMACEUTICAL CO., LTD |
Score | 2.6481292 |
Snippet | The present invention provides a heterocyclic compound represented by General Formula (1): wherein R1 is a group R5-Z1-, etc., Z1 is a lower alkylene group,... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | BANDAGES, DRESSINGS OR ABSORBENT PADS CHEMISTRY DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF,TUBULAR STRUCTURES OF THE BODY, E.G. STENTS FILTERS IMPLANTABLE INTO BLOOD VESSELS FIRST-AID KITS FOMENTATION HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROSTHESES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TREATMENT OR PROTECTION OF EYES OR EARS |
Title | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20100519&DB=EPODOC&locale=&CC=MX&NR=2010004893A |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_mFPVNp6JOpYj0rdi1XevAIl2a0on9YHZSn8bSpiDCNlzFf99Ltume9hBIcnAkgct95X4BuEMVYrGK65pRcnRQuqWlMYd3tdKxS73DqkqXWHpRbIcj6znv5g34XNfCSJzQHwmOiBJVoLzX8r6e_wexfPm2cnHPPnBq9hRkrq-uvOOOtEhUv-_SNPETohLiRrkaD5c0XSCteDuwi3a0I8SBvvVFWcp8U6cER7CXIrtpfQwNvmjBAVl_vdaC_WiV8cbuSvgWJ_AYUrQ9E_JOXgZEIUmUJqPYVzxsaegNI4_QUSbgDZa014GIPilZSIc0CU7hNqAZCTVcxvhv0-Mo31iyeQbN6WzKz0HpTbhR2AJyxqqswijYg14apsktbtslji-gvYXR5VZqGw7XyfFO7wqa9dc3v0adW7MbeVa_NPl_-A |
link.rule.ids | 230,309,783,888,25576,76876 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_mFOebTkWdH0Wkb8Wu7VoHFunSlE6XtsxOuqdh2xRE2Iar-O97zTbd0x4CSQ6OJHC5r9wvAHeoQoy04Kqi5RwdlE5uKKnFO0pumbnaTotCFVh6LDD9kfGcdJIafK5rYQRO6I8AR0SJylDeS3Ffz_-DWK54W7m4Tz9wavbkxbYrr7zjtrBIZLdn0yh0QyITYrNEDoZLmlohrTg7sIs2tlWJA33rVWUp802d4h3CXoTspuUR1PiiCQ2y_nqtCftslfHG7kr4Fsfw6FO0PUMyJoM-kUjIonAUuJKDLfKdIXMIHcUVvMGS9tqvok9S7NMhDb0TuPVoTHwFlzH52_SEJRtL1k-hPp1N-RlI3XeuZWYFOWMURqZl6YOaa7rODW6aOY7PobWF0cVW6g00_JgNJoN-8NKCg3WivN29hHr59c2vUP-W6bU4t19g9YLr |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=HETEROCYCLIC+COMPOUND+AND+PHARMACEUTICAL+COMPOSITION+THEREOF&rft.inventor=HASHIMOTO%2C+NORIKAZU&rft.inventor=TABUSA%2C+FUJIO&rft.inventor=KOJIMA%2C+YUTAKA&rft.inventor=TAKASU%2C+HIDEKI&rft.inventor=KAN%2C+KEIZO&rft.inventor=OHI%2C+NAOTO&rft.inventor=NAKAGAWA%2C+TAKASHI&rft.inventor=MIYAJIMA%2C+KEISUKE&rft.inventor=YASUMURA%2C+KOICHI&rft.inventor=YOSHIDA%2C+KENJI&rft.inventor=FUJITA%2C+SHIGEKAZU&rft.inventor=SEKIGUCHI%2C+KAZUO&rft.inventor=IIDA%2C+MASATOSHI&rft.inventor=MOTOYAMA%2C+MASAAKI&rft.inventor=HARADA%2C+YASUO&rft.inventor=KODAMA%2C+TAKESHI&rft.inventor=MATSUYAMA%2C+HIRONORI&rft.inventor=FUKUSHIMA%2C+TAE&rft.inventor=SUMIDA%2C+TAKUMI&rft.inventor=SAKAMOTO%2C+MAKOTO&rft.date=2010-05-19&rft.externalDBID=A&rft.externalDocID=MX2010004893A |